---
title: "IMUX.US (IMUX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IMUX.US/news.md"
symbol: "IMUX.US"
name: "IMUX.US"
parent: "https://longbridge.com/en/quote/IMUX.US.md"
datetime: "2026-05-19T17:26:48.251Z"
locales:
  - [en](https://longbridge.com/en/quote/IMUX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IMUX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IMUX.US/news.md)
---

# IMUX.US (IMUX.US) — Related News

### [Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec](https://longbridge.com/en/news/286894831.md)
*2026-05-19T10:30:24.000Z*
> Immunic has appointed Michael W. Bonney as chair of the board, effective May 16, 2026, replacing interim chair Simona Sk

### [Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | IMUX Stock News](https://longbridge.com/en/news/286894992.md)
*2026-05-19T02:30:45.000Z*
> Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | IMUX Stock 

### [Immunic (IMUX) Gets a Buy from LifeSci Capital](https://longbridge.com/en/news/286679219.md)
*2026-05-17T16:46:52.000Z*
> LifeSci Capital's Sam Slutsky has maintained a Buy rating on Immunic (IMUX) with a price target of $56.00. Slutsky, who 

### [IMMUNIC, INC. 1Q 2026: Revenue $0 Net loss $32.6M — 10-Q Summary](https://longbridge.com/en/news/286244201.md)
*2026-05-13T10:41:00.000Z*
> IMMUNIC, INC. reported Q1 2026 results with $0 revenue and a net loss of $32.6M, widening from a $25.5M loss in Q1 2025.

### [Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update | IMUX Stock News](https://longbridge.com/en/news/286241996.md)
*2026-05-13T02:30:34.000Z*
> Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update | IMUX Stock News

### [06:30 ETImmunic to Participate in Investor and Medical Conferences in May](https://longbridge.com/en/news/284746729.md)
*2026-04-30T10:32:20.000Z*
> Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company, announced its participation in several investor and me